Figueira HCM, Villarroel DM, Hernández A, Moret Y, Rosas NRV

Language: Spanish
References: 18
Page: 27-33
PDF size: 369.33 Kb.

ABSTRACT

Introduction: 5-fluorouracil (5-FU) is a drug used in the treatment of basal cell carcinoma (BCC). It inhibits thymidylate synthetase, an enzyme necessary for DNA synthesis that causes cell death. Molecular studies focusing on the patched protein homologous tumor suppressor gene pathway (PTCH) have produced a treatment approach targeting BCC. Odontogenic keratocysts (OKC) are known to develop through PTCH gene mutations similar to BCC. Due to this similarity in the molecular etiopathogenesis of OKC, it is believed that the topical use of 5-fluorouracil in the management of this pathology decreases the recurrence rate. Clinical case: a 54-year-old male patient, who upon clinical and radiographic examination revealed a radiolucent, multilobular image, with diffuse edges, in the region of the body and left mandibular angle, for which incisional biopsy was performed, which reported the histopathological result as odontogenic keratocyst. Under general anesthesia, enucleation and curettage, peripheral ostectomy, and topical application of 5-fluorouracil are performed. Patient is evaluated in a late postoperative period, with computed tomography, where adequate healing process and neoformation bone in the region of the body and left mandibular angle. Conclusions: 5-FU is a novel, effective and targeted treatment for OKC with lower recurrence rates and less morbidity, the advantages of topical 5-FU includes short operative time, availability, technical simplicity, reduced morbidity, low cost, with low or no recurrence, thus reducing the need for a second surgery.

REFERENCES

1. Shear M, Speight P. Cysts of the oral and maxillofacial regions. 4^th ed. Oxford: Blackwell Publishing; 2008.

2. Shear M. The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 1. Clinical and early experimental evidence of aggressive behaviour. Oral Oncol. 2002; 38: 219-226.

3. Pogrel MA. The keratocystic odontogenic tumor. Oral Maxillofac Surg Clin North Am. 2013; 25 (1): 21-30.

4. Kaczmarzyk T, Mojsa I, Stypulkowska J. A systematic review of the recurrence rate for Keratocystic odontogenic tumour in relation to treatment modalities. Int J Oral Maxillofac Surg. 2012; 41 (6): 756-767.

5. Bell RB, Dierks EJ. Treatment options for the recurrent odontogenic keratocyst. Oral Maxillofac Surg Clin North Am. 2003; 15 (3): 429-446.

6. Ghali GE, Connor MS. Surgical management of the odontogenic keratocyst. Oral Maxillofac Surg Clin North Am. 2003; 15 (3): 383-392.

7. Blanas N, Freund B, Schwartz M, Furst IM. Systematic review of the treatment and prognosis of the odontogenic keratocyst. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90 (5): 553-558.

8. Beach DF, Somer R. Novel approach to Gorlin syndrome: a patient treated with oral capecitabine. J Clin Oncol. 2011; 29 (14): e397-401.

9. Ren C, Amm HM, DeVilliers P, Wu Y, Deatherage JR, Liu Z, et al. Targeting the sonic hedgehog pathway in keratocystic odontogenic tumor. J Biol Chem. 2012; 287 (32): 27117-27125.

10. Qu J, Yu F, Hong Y, Guo Y, Sun L, Li X, et al. Underestimated PTCH1 mutation rate in sporadic keratocystic odontogenic tumors. Oral Oncol. 2015; 51 (1): 40-45.

11. Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial Basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007; 33 (4): 433-439; discussion 440.

12. Ledderhof NJ, Caminiti MF, Bradley G, Lam DK. Topical 5-fluorouracil is a novel targeted therapy for the keratocystic odontogenic tumor. J Oral Maxillofac Surg. 2017; 75 (3): 514-524.

13. Rui Z, Li-Ying P, Jia-Fei Q, Ying-Ying H, Feng C, Tie-Jun L. Smoothened gene alterations in keratocystic odontogenic tumors. Head Face Med. 2014; 10: 36.

14. Balamurugan R. 5 fluorouracil: trend setter in the management of odontogenic keratocyst. J Case Stud Cl Trials. 2019;1(1).

15. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3 (5): 330-338.

16. Evrard A, Cuq P, Ciccolini J, Vian L, Cano JP. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer. 1999; 80 (11): 1726-1733.

17. Akhter Lone P, Ahmed Wani N, Ahmed Janbaz Z, Bibi M, Kour A. Topical 5-fluorouracil application in management of odontogenic keratocysts. J Oral Biol Craniofac Res. 2020; 10 (4): 404-406.

18. Caminiti MF, El-Rabbany M, Jeon J, Bradley G. 5-fluorouracil is associated with a decreased recurrence risk in odontogenic keratocyst management: a retrospective cohort study. J Oral Maxillofac Surg. 2021; 79 (4): 814-821.